231 related articles for article (PubMed ID: 29550521)
1. Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets.
Makhoul S; Walter E; Pagel O; Walter U; Sickmann A; Gambaryan S; Smolenski A; Zahedi RP; Jurk K
Nitric Oxide; 2018 Jun; 76():71-80. PubMed ID: 29550521
[TBL] [Abstract][Full Text] [Related]
2. Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase) - cGMP (cyclic guanosine monophosphate) - PKG (protein kinase G) pathway.
Chen L; Zhou X; Deng Y; Yang Y; Chen X; Chen Q; Liu Y; Fu X; Kwan HY; You Y; Jin W; Zhao X
J Ethnopharmacol; 2023 Jan; 300():115705. PubMed ID: 36099983
[TBL] [Abstract][Full Text] [Related]
3. The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.
Reiss C; Mindukshev I; Bischoff V; Subramanian H; Kehrer L; Friebe A; Stasch JP; Gambaryan S; Walter U
Br J Pharmacol; 2015 Nov; 172(21):5199-210. PubMed ID: 26282717
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of cGMP-dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking soluble guanylyl cyclase.
Rukoyatkina N; Walter U; Friebe A; Gambaryan S
Thromb Haemost; 2011 Nov; 106(5):922-33. PubMed ID: 21800013
[TBL] [Abstract][Full Text] [Related]
5. The Role of NO/sGC/cGMP/PKG Signaling Pathway in Regulation of Platelet Function.
Gambaryan S
Cells; 2022 Nov; 11(22):. PubMed ID: 36429131
[TBL] [Abstract][Full Text] [Related]
6. The NO/cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I.
Danielewski O; Schultess J; Smolenski A
Thromb Haemost; 2005 Feb; 93(2):319-25. PubMed ID: 15711749
[TBL] [Abstract][Full Text] [Related]
7. Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease.
Cortese-Krott MM; Mergia E; Kramer CM; Lückstädt W; Yang J; Wolff G; Panknin C; Bracht T; Sitek B; Pernow J; Stasch JP; Feelisch M; Koesling D; Kelm M
Redox Biol; 2018 Apr; 14():328-337. PubMed ID: 29024896
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition.
Dangel O; Mergia E; Karlisch K; Groneberg D; Koesling D; Friebe A
J Thromb Haemost; 2010 Jun; 8(6):1343-52. PubMed ID: 20149081
[TBL] [Abstract][Full Text] [Related]
9. The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system.
Correia SS; Liu G; Jacobson S; Bernier SG; Tobin JV; Schwartzkopf CD; Atwater E; Lonie E; Rivers S; Carvalho A; Germano P; Tang K; Iyengar RR; Currie MG; Hadcock JR; Winrow CJ; Jones JE
J Neuroinflammation; 2021 Sep; 18(1):213. PubMed ID: 34537066
[TBL] [Abstract][Full Text] [Related]
10. Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation.
Zhang G; Xiang B; Dong A; Skoda RC; Daugherty A; Smyth SS; Du X; Li Z
Blood; 2011 Sep; 118(13):3670-9. PubMed ID: 21803853
[TBL] [Abstract][Full Text] [Related]
11. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
12. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
13. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
[TBL] [Abstract][Full Text] [Related]
14. Novel roles of cAMP/cGMP-dependent signaling in platelets.
Smolenski A
J Thromb Haemost; 2012 Feb; 10(2):167-76. PubMed ID: 22136590
[TBL] [Abstract][Full Text] [Related]
15. Conventional and Unconventional Mechanisms for Soluble Guanylyl Cyclase Signaling.
Gao Y
J Cardiovasc Pharmacol; 2016 May; 67(5):367-72. PubMed ID: 26452163
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide stimulates human sperm motility via activation of the cyclic GMP/protein kinase G signaling pathway.
Miraglia E; De Angelis F; Gazzano E; Hassanpour H; Bertagna A; Aldieri E; Revelli A; Ghigo D
Reproduction; 2011 Jan; 141(1):47-54. PubMed ID: 20965947
[TBL] [Abstract][Full Text] [Related]
17. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.
Friebe A; Müllershausen F; Smolenski A; Walter U; Schultz G; Koesling D
Mol Pharmacol; 1998 Dec; 54(6):962-7. PubMed ID: 9855623
[TBL] [Abstract][Full Text] [Related]
18. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
19. The bradykinin-cGMP-PKG pathway augments insulin sensitivity via upregulation of MAPK phosphatase-5 and inhibition of JNK.
Frigolet ME; Thomas G; Beard K; Lu H; Liu L; Fantus IG
Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E321-E334. PubMed ID: 28679626
[TBL] [Abstract][Full Text] [Related]
20. Sodium azide, a bacteriostatic preservative contained in commercially available laboratory reagents, influences the responses of human platelets via the cGMP/PKG/VASP pathway.
Russo I; Del Mese P; Viretto M; Doronzo G; Mattiello L; Trovati M; Anfossi G
Clin Biochem; 2008 Mar; 41(4-5):343-9. PubMed ID: 18022387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
